Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
B. lactis (BB-12 / HN019) vs L. rhamnosus GG: L. rhamnosus GG has the stronger overall evidence (6 vs 6/10); they're alternatives for improve digestion — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
L. rhamnosus GG wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both B. lactis (BB-12 / HN019) and L. rhamnosus GG have evidence — compare verdict strength side-by-side.
1-10 billion CFU daily for BB-12 (1 billion is enough); 10-20 billion CFU daily for HN019 if transit is the goal
any
Capsule or sachet standardized to a named strain (BB-12 or HN019)
10-20 billion CFU (1-2 x 10^10) daily; 10 billion CFU/day is the effective floor
any
Capsule standardized to ATCC 53103
2 weeks
4 weeks
n/a
n/a
During the antibiotic course
During hospital stay
n/a
n/a
Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults.
Scand J Gastroenterol (2011) · Rct · n=100
Whole-gut transit fell 49 to 21 hours on high dose (p<0.001) and 60 to 41 hours on low dose (p=0.01); placebo unchanged
Eight-Week Supplementation With Bifidobacterium lactis HN019 and Functional Constipation: A Randomized Clinical Trial.
JAMA Netw Open (2024) · Rct · n=229
Primary outcome (change in complete spontaneous bowel movements per week): +0.80 with HN019 vs +0.66 placebo — no difference
Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial.
Gut Microbes (2018) · Rct · n=228
No significant differences vs placebo in the primary outcome (colonic transit time) or any secondary outcome
Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children.
N Engl J Med (2018) · Rct · n=971
Primary outcome (modified Vesikari score >=9 within 14 days): 11.8% with LGG vs 12.6% placebo; RR 0.96 (0.68-1.35), P=0.83
Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults.
Aliment Pharmacol Ther (2015) · Meta analysis
Antibiotic-associated diarrhea fell from 22.4% to 12.3%; RR 0.49 (0.29-0.83) pooled across 11 RCTs, n=1,308 (12 RCTs, n=1,499 included overall)
Probiotics for treating acute infectious diarrhoea.
Cochrane Database Syst Rev (2020) · Meta analysis
In studies at low risk of bias, no difference in diarrhea lasting >=48 hours (RR 1.00, 0.91-1.09; moderate certainty)
L. rhamnosus GG has a higher evidence score (6/10 vs 6/10) and wins in 1 of 3 categories.
For improve digestion, L. rhamnosus GG has a higher relevance score (72 vs 68).
No known interactions between B. lactis (BB-12 / HN019) and L. rhamnosus GG have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.